FULC
Price
$7.27
Change
-$0.39 (-5.09%)
Updated
Sep 8, 04:59 PM (EDT)
Capitalization
393.25M
65 days until earnings call
MNKD
Price
$5.57
Change
+$0.03 (+0.54%)
Updated
Sep 8, 04:59 PM (EDT)
Capitalization
1.71B
63 days until earnings call
Interact to see
Advertisement

FULC vs MNKD

Header iconFULC vs MNKD Comparison
Open Charts FULC vs MNKDBanner chart's image
Fulcrum Therapeutics
Price$7.27
Change-$0.39 (-5.09%)
Volume$2.31K
Capitalization393.25M
MannKind
Price$5.57
Change+$0.03 (+0.54%)
Volume$91.11K
Capitalization1.71B
FULC vs MNKD Comparison Chart in %
Loading...
FULC
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
MNKD
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
FULC vs. MNKD commentary
Sep 09, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is FULC is a Hold and MNKD is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Sep 09, 2025
Stock price -- (FULC: $7.66 vs. MNKD: $5.54)
Brand notoriety: FULC and MNKD are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: FULC: 91% vs. MNKD: 170%
Market capitalization -- FULC: $393.25M vs. MNKD: $1.71B
FULC [@Biotechnology] is valued at $393.25M. MNKD’s [@Biotechnology] market capitalization is $1.71B. The market cap for tickers in the [@Biotechnology] industry ranges from $101.34B to $0. The average market capitalization across the [@Biotechnology] industry is $1.92B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

FULC’s FA Score shows that 1 FA rating(s) are green whileMNKD’s FA Score has 0 green FA rating(s).

  • FULC’s FA Score: 1 green, 4 red.
  • MNKD’s FA Score: 0 green, 5 red.
According to our system of comparison, MNKD is a better buy in the long-term than FULC.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

FULC’s TA Score shows that 6 TA indicator(s) are bullish while MNKD’s TA Score has 6 bullish TA indicator(s).

  • FULC’s TA Score: 6 bullish, 4 bearish.
  • MNKD’s TA Score: 6 bullish, 4 bearish.
According to our system of comparison, both FULC and MNKD are a good buy in the short-term.

Price Growth

FULC (@Biotechnology) experienced а +18.21% price change this week, while MNKD (@Biotechnology) price change was +20.70% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +2.13%. For the same industry, the average monthly price growth was +10.99%, and the average quarterly price growth was +33.00%.

Reported Earning Dates

FULC is expected to report earnings on Nov 12, 2025.

MNKD is expected to report earnings on Nov 11, 2025.

Industries' Descriptions

@Biotechnology (+2.13% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
MNKD($1.71B) has a higher market cap than FULC($393M). FULC YTD gains are higher at: 62.979 vs. MNKD (-13.841). MNKD has higher annual earnings (EBITDA): 79.1M vs. FULC (-81.28M). FULC has more cash in the bank: 214M vs. MNKD (179M). FULC has less debt than MNKD: FULC (7.57M) vs MNKD (46.8M). MNKD has higher revenues than FULC: MNKD (302M) vs FULC (0).
FULCMNKDFULC / MNKD
Capitalization393M1.71B23%
EBITDA-81.28M79.1M-103%
Gain YTD62.979-13.841-455%
P/E RatioN/A50.64-
Revenue0302M-
Total Cash214M179M120%
Total Debt7.57M46.8M16%
FUNDAMENTALS RATINGS
FULC vs MNKD: Fundamental Ratings
FULC
MNKD
OUTLOOK RATING
1..100
5050
VALUATION
overvalued / fair valued / undervalued
1..100
24
Undervalued
56
Fair valued
PROFIT vs RISK RATING
1..100
10045
SMR RATING
1..100
97100
PRICE GROWTH RATING
1..100
3938
P/E GROWTH RATING
1..100
10097
SEASONALITY SCORE
1..100
n/a50

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

FULC's Valuation (24) in the null industry is in the same range as MNKD (56) in the Biotechnology industry. This means that FULC’s stock grew similarly to MNKD’s over the last 12 months.

MNKD's Profit vs Risk Rating (45) in the Biotechnology industry is somewhat better than the same rating for FULC (100) in the null industry. This means that MNKD’s stock grew somewhat faster than FULC’s over the last 12 months.

FULC's SMR Rating (97) in the null industry is in the same range as MNKD (100) in the Biotechnology industry. This means that FULC’s stock grew similarly to MNKD’s over the last 12 months.

MNKD's Price Growth Rating (38) in the Biotechnology industry is in the same range as FULC (39) in the null industry. This means that MNKD’s stock grew similarly to FULC’s over the last 12 months.

MNKD's P/E Growth Rating (97) in the Biotechnology industry is in the same range as FULC (100) in the null industry. This means that MNKD’s stock grew similarly to FULC’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
FULCMNKD
RSI
ODDS (%)
Bearish Trend 4 days ago
75%
Bearish Trend 4 days ago
71%
Stochastic
ODDS (%)
Bullish Trend 4 days ago
81%
Bearish Trend 4 days ago
79%
Momentum
ODDS (%)
Bullish Trend 4 days ago
83%
Bullish Trend 4 days ago
77%
MACD
ODDS (%)
Bullish Trend 4 days ago
90%
Bullish Trend 4 days ago
72%
TrendWeek
ODDS (%)
Bullish Trend 4 days ago
87%
Bullish Trend 4 days ago
80%
TrendMonth
ODDS (%)
Bullish Trend 4 days ago
88%
Bullish Trend 4 days ago
77%
Advances
ODDS (%)
Bullish Trend 4 days ago
87%
Bullish Trend 7 days ago
80%
Declines
ODDS (%)
Bearish Trend 7 days ago
85%
Bearish Trend 5 days ago
80%
BollingerBands
ODDS (%)
Bearish Trend 4 days ago
78%
Bearish Trend 4 days ago
84%
Aroon
ODDS (%)
Bullish Trend 4 days ago
77%
Bullish Trend 4 days ago
90%
View a ticker or compare two or three
Interact to see
Advertisement
FULC
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
MNKD
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
JMGFX56.410.02
+0.04%
JPMorgan Mid Cap Growth R5
DDIAX15.86N/A
N/A
Macquarie Wealth Builder A
GCPCX20.73-0.01
-0.05%
Gateway Equity Call Premium C
IEOSX16.31-0.04
-0.24%
Voya Large Cap Growth Port S
HSSAX32.82-0.24
-0.73%
Emerald Finance & Bking Innovt Fd A

FULC and

Correlation & Price change

A.I.dvisor indicates that over the last year, FULC has been loosely correlated with ANNX. These tickers have moved in lockstep 40% of the time. This A.I.-generated data suggests there is some statistical probability that if FULC jumps, then ANNX could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To FULC
1D Price
Change %
FULC100%
+11.34%
ANNX - FULC
40%
Loosely correlated
+0.93%
VRDN - FULC
40%
Loosely correlated
+0.43%
RARE - FULC
39%
Loosely correlated
+1.73%
MRNA - FULC
38%
Loosely correlated
+3.54%
BMRN - FULC
38%
Loosely correlated
+1.80%
More

MNKD and

Correlation & Price change

A.I.dvisor indicates that over the last year, MNKD has been loosely correlated with CYTK. These tickers have moved in lockstep 46% of the time. This A.I.-generated data suggests there is some statistical probability that if MNKD jumps, then CYTK could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To MNKD
1D Price
Change %
MNKD100%
+3.75%
CYTK - MNKD
46%
Loosely correlated
+6.55%
UTHR - MNKD
39%
Loosely correlated
+5.27%
MLYS - MNKD
38%
Loosely correlated
+5.07%
DAWN - MNKD
37%
Loosely correlated
+1.89%
FULC - MNKD
36%
Loosely correlated
+11.34%
More